Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fecal microbiota transplantation (FMT) is an investigational live biotherapeutic therapy being studied for psychiatric and gastrointestinal disorders. [8] It involves transferring gut bacteria and other microbes from a healthy, screened donor to a patient's gut, with the goal of restoring a balanced microbial community. [8] This approach is based on the growing understanding of the microbiome-gut-brain axis, a communication pathway that links the gut and the brain. [2, 9] Research led by Dr. Valerie Taylor at the University of Calgary is specifically evaluating the effectiveness, safety, and tolerability of oral FMT (in capsule form) for adults with Major Depressive Disorder (MDD), including those with co-occurring Irritable Bowel Syndrome (IBS). [2, 3] A Phase 2/3 clinical trial is underway to assess if modulating the gut microbiome with FMT can alleviate symptoms of depression and IBS. [3, 14]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fecal microbiota transplantation (University of Calgary).